Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norr…

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conwa…

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S, Dunlop…

Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. Int J Drug Policy. 2017 Jun 16;45:64-69. doi: 10.1016/j.drugpo.2017.0…

Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Int J Drug Policy. 2017 Jun 23. pi…

BfArM, Pressemitteilung Nr. 9/17, 22.06.2017 http://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2017/pm9-2017.html